The F.D.A. Approves a New Pill to Slash Cholesterol Levels

The new pills can lower cholesterol levels far below what can be achieved with statins, clinical trials have shown.
The Caledonian-Record

Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA ® (enlicitide) tablets 20 mg as an adjunct ...